Search clinical trials for: EBV Positive Non-Hodgkin's Lymphoma

Total 21296 results

Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma (CILESTE)

EBV-Related Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | EBV-Related Lymphoproliferative Disorder

United States
Baylor College of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); The Methodist... and other collaborators

Recruiting

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)

Lymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Lymphoproliferative Disease

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (TGF-beta)

Lymphoma | Lymphoma, Non-Hodgkin | Relapse | Hodgkin's Disease

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)

Lymphoproliferative Disorders | Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | NonHodgkin Lymphoma | EBV-Related PTLD | EBV Related Lymphoma | EBV Related Hodgkin's Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | EBV Positive Plasma Cell Neoplasm

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (ANGELA)

Hodgkin Disease | Non-Hodgkins Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma (ALDI)

Non-Hodgkin Lymphoma | Hodgkins Lymphoma

United States
Ciusss de L'Est de l'Île de Montréal

Recruiting

Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

EBV Associated Lymphoma

Canada
Guangzhou Excelmab Inc.

Recruiting

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

CD20-positive Non-Hodgkin Lymphoma

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Registry for People With T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Primary Cutaneous Anaplastic Large... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Cord Blood Transplant in Adults With Blood Cancers

Non-Hodgkin's Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloproliferative Disorder | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

CD20-positive B-cell Non-Hodgkin's Lymphoma

China
Nationwide Children's Hospital

Not yet recruiting

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Acute Lymphoblastic Leukemia, in Relapse | B Cell Leukemia | B-cell Non Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphoblastic Leukemia With Failed Remission

United States
Patrick C. Johnson, MD
AstraZeneca

Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3b Follicular Lymphoma | Refractory Aggressive B-cell Lymphomas | Aggressive B-cell NHL | De Novo or Transformed Indolent B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | T Cell/Histiocyte-rich Large B-cell Lymphoma and other conditions

United States
Sun Yat-sen University
Fudan University; Antengene Corporation

Recruiting

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos

China
Schrödinger, Inc.

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Burkitt Lymphoma | Plasmablastic Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Primary Effusion Lymphoma | DLBCL | High-grade B-cell Lymphoma | Primary Mediastinal... and other conditions

United States, Moldova, Republic of
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
Dren Bio
Novotech

Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Aggressive NK Cell Leukemia | Hepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Subcutaneous Panniculitis-Like T-Cell Lymphoma | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | LGLL - Large Granular Lymphocytic Leukemia | Primary Cutaneous T-Cell Lymphoma - Category and other conditions

United States, Australia, France, Spain
Chimagen Biosciences, Ltd

Recruiting

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

Non-Hodgkin's Lymphoma (Disorder) | Acute Lymphoid Leukemia, Disease (Disorder)

United States
Viracta Therapeutics, Inc.

Recruiting

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

EBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOS

United States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Germany, Canada, Brazil, Australia, France, Malaysia, Hong Kong, Israel
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
Huiqiang Huang

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, Nos

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Huiqiang Huang

Recruiting

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Eutilex

Recruiting

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

EBV Associated Extranodal NK/T-cell Lymphoma | EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma

Korea, Republic of
Ottawa Hospital Research Institute

Recruiting

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

Canada
ViGenCell Inc.

Recruiting

VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients

Extranodal NK/T-cell Lymphoma

Korea, Republic of
Imugene Limited

Recruiting

Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

Non-Hodgkin Lymphoma | B-cell Acute Lymphoblastic Leukemia

United States
Autolus Limited

Recruiting

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T Cell Non-Hodgkin Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified

United Kingdom, Spain
National Cancer Institute (NCI)

Recruiting

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Lymphoma | Epstein-Barr Virus Infections | Lymphoproliferative Disorder | Disorders, Lymphoproliferative

United States
St. Jude Children's Research Hospital

Recruiting

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Myeloid Sarcoma | Chronic Myeloid Leukemia (CML) | Non-Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (MABEL)

Nasopharyngeal Carcinoma | Hodgkin Disease | Non-Hodgkin Lymphoma | Severe Chronic Active Epstein Barr Virus | T/NK-lymphoproliferative Disease | Smooth Muscle Tumor

United States
Chinese PLA General Hospital

Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

China
Masonic Cancer Center, University of Minnesota

Recruiting

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Follicular Lymphoma | Multiple Myeloma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myelodysplasia | Acute Myeloid Leukemia... and other conditions

United States
Wake Forest University Health Sciences

Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Myelodysplastic Syndromes | Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease | Germ Cell Neoplasms | Immunodeficiency Diseases

United States
Massachusetts General Hospital

Recruiting

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)

Autoimmune Diseases | Multiple Myeloma | Hodgkin Disease | AL Amyloidosis | Myelofibrosis | Chronic Kidney Disease | Sickle Cell Anemia | Thalassemia | Aplastic Anemia | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Non-Hodgkin... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditions

United States
AbbVie
Genentech, Inc.

Active, not recruiting

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Non-Hodgkin's Lymphoma | Hematological Malignancies | Chronic Lymphoid Leukemia | CD20-Positive Lymphoid Malignancies

United States, Australia
University College, London
Bloodwise

Completed

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (UK-Haplo)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia | Chronic Lymphocytic Leukaemia | Acute Lymphoblastic Leukaemia | Chronic Myeloid Leukaemia | Acquired Bone Marrow Failure Syndromes | Other Haematological Malignancies; Unrelated HSCT Indicated

United Kingdom
University of Washington
Genentech, Inc.

Suspended

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditions

United States
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (ATECRAB)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States

Search clinical trials for: EBV Positive Non-Hodgkin's Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations